https://doi.org/10.1016/j.apsb.2025.10.028
This new article publication from Acta Pharmaceutica Sinica B , discusses how structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity.
Recent advances in ion channel structural biology have enhanced structure-based drug design, yet lipid-occupied binding pockets—often large and flat—remain a major hurdle for developing selective small molecules. TRPC5, a brain-enriched channel regulating depression and anxiety, is a promising therapeutic target, but current preclinical candidates suffer from moderate off-target effects. To address this, the authors of this article designed macrocyclic TRPC5 inhibitors using structure-guided macrocyclization, overcoming lipid-binding site challenges. Among these, JDIC-127 exhibited unprecedented potency with IC 50 of 374 pmol/L—200-fold more potent than HC-070—and exceptional selectivity. Its specificity arises from interactions with unique structural features near the S5 and S6 helices of TRPC5, minimizing activity against related TRPC channels and other ion channels. This selective inhibition aligns with preclinical evidence supporting JDIC-127's potential in treating neuropsychiatric disorders. The study demonstrates how macrocycles stabilize ligand conformations, enhance affinity, and achieve selectivity in lipid-dominated binding sites. It also highlights the synergy between macrocyclic design, cryo-EM, and computational modeling to address longstanding obstacles in ion channel drug discovery. JDIC-127 serves as a proof-of-concept for the application of macrocyclization in ion channel pharmacology, offering a roadmap for developing innovative therapeutics targeting TRP channels and beyond, with implications for a wide range of diseases.
Keywords: TRPC5, Ion channel, Structure-based drug design, Macrocyclization, Selectivity, Cryo-EM, Antidepressant, Anxiolytic
Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383525007063-ga1_lrg.jpg
The macrocyclic compound JDIC-127 has demonstrated exceptional potency towards TRPC5, with an IC 50 of 374 pmol/L, which is 200-fold more potent than HC-070, and exhibits significant selectivity against other TRP channels.
# # # # # #
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association .
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on ScienceDirect ( https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b ).
Submissions to APSB may be made using Editorial Manager ® ( https://www.editorialmanager.com/apsb/default.aspx ).
CiteScore: 24.3
Impact Factor: 14.6 (Top 6 journal in the category of Pharmacology and pharmacy)
JIF without self-citation: 13.8
ISSN 2211-3835
# # # # #
Tong Che, Yixiang Chen, Xinyu Cheng, Han Hu, Xiaoyun Wu, Yuting Zhang, Xiaoqiang Yang, Yinzhen Liu, Hui Liu, Weiwei Nan, Shuangyan Wan, Mingxing Yang, Bo Zeng, Jian Li, Jin Zhang, Bing Xiong, Structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity, Acta Pharmaceutica Sinica B, Volume 16, Issue 1, 2026, Pages 371-386, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2025.10.028